China approves Eli Lilly’s weight loss pill orforglipron

China has approved Eli Lilly’s weight‑loss medication orforglipron, making the company the first drugmaker with a GLP‑1 weight‑loss pill cleared in the Chinese market. The regulatory green light sent Eli Lilly’s shares higher, reflecting investor optimism about the drug’s commercial potential and its role in expanding the company’s presence in the growing obesity‑treatment sector.